approval
saveELREXFIO (ELRANATAMAB) — FDA approval
community read0 votes
Sponsor: PFIZER INC. Form: SOLUTION. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 7
- phase 3 completionCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)Apr 27, 2026 · 163d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalMar 25, 2026 · 196d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalFeb 19, 2026 · 230d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalJul 8, 2025 · 456d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalSep 10, 2024 · 757d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalDec 13, 2023 · 1029d ago
- approvalELREXFIO (ELRANATAMAB) — FDA approvalAug 14, 2023 · 1150d ago
same company · ±60 days · 6
- device pmaFerrosan Meidcal Devices A/S — SURGIFLO Hemostatic Matrix Kit with Thrombin (PMA supplement)Jul 9, 2025
- approvalelranatamab: ELREXFIO (ELRANATAMAB) — FDA approvalJul 8, 2025
- recallPfizer Inc. recall (Cls II)Jul 2, 2025
- device pmaFerrosan Meidcal Devices A/S — SURGIFLO® Hemostatic Matrix; SURGIFLO® Hemostatic Matrix Kit with Thrombin (PMA supplement)Jul 18, 2025
- approvalrimegepant sulfate ODT: NURTEC ODT (RIMEGEPANT SULFATE) — FDA approvalAug 1, 2025
- recallPfizer Inc. recall (Cls II)Aug 6, 2025
comments(0)
5-min edit window · permanent after that